scholarly journals Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease

2021 ◽  
Vol 22 (14) ◽  
pp. 7348
Author(s):  
Olivia Wegrzyniak ◽  
Maria Rosestedt ◽  
Olof Eriksson
Keyword(s):  
Liver Disease ◽  
Molecular Imaging ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Imaging Techniques ◽  
Current Status ◽  
Nonalcoholic Fatty Liver ◽  
Positron Emission ◽  
Activated Fibroblasts

Pathological fibrosis of the liver is a landmark feature in chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Diagnosis and assessment of progress or treatment efficacy today requires biopsy of the liver, which is a challenge in, e.g., longitudinal interventional studies. Molecular imaging techniques such as positron emission tomography (PET) have the potential to enable minimally invasive assessment of liver fibrosis. This review will summarize and discuss the current status of the development of innovative imaging markers for processes relevant for fibrogenesis in liver, e.g., certain immune cells, activated fibroblasts, and collagen depositions.

scholarly journals Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)

Cells ◽  
2019 ◽  
Vol 8 (8) ◽  
pp. 845 ◽  
Author(s):  
Hannah Drescher ◽  
Sabine Weiskirchen ◽  
Ralf Weiskirchen
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Nonalcoholic Steatohepatitis ◽  
Fatty Liver Disease ◽  
Sampling Error ◽  
Imaging Techniques ◽  
Current Status ◽  
Nonalcoholic Fatty Liver ◽  
Public Health Burden

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countries with almost 25% affected adults worldwide. The growing public health burden is getting evident when considering that NAFLD-related liver transplantations are predicted to almost double within the next 20 years. Typically, hepatic alterations start with simple steatosis, which easily progresses to more advanced stages such as nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis. This course of disease finally leads to end-stage liver disease such as hepatocellular carcinoma, which is associated with increased morbidity and mortality. Although clinical trials show promising results, there is actually no pharmacological agent approved to treat NASH. Another important problem associated with NASH is that presently the liver biopsy is still the gold standard in diagnosis and for disease staging and grading. Because of its invasiveness, this technique is not well accepted by patients and the method is prone to sampling error. Therefore, an urgent need exists to find reliable, accurate and noninvasive biomarkers discriminating between different disease stages or to develop innovative imaging techniques to quantify steatosis.

scholarly journals Concepts and Treatment Approaches in Nonalcoholic Fatty Liver Disease

2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Dina L. Halegoua-De Marzio ◽  
Jonathan M. Fenkel
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
De Novo ◽  
Imaging Techniques ◽  
De Novo Lipogenesis ◽  
Central Adiposity ◽  
Preventative Care ◽  
Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease (NAFLD) affects up to 30% of adults and is the most common liver disease in Western nations. NAFLD is associated with central adiposity, insulin resistance, type 2 diabetes mellitus, hyperlipidemia, and cardiovascular disease. It encompasses the entire spectrum of fatty liver diseases from simple steatosis to nonalcoholic steatohepatitis (NASH) with lobular/portal inflammation, hepatocellular necrosis, and fibrosis. Of those who develop NASH, 15–25% will progress to end stage liver disease and hepatocellular carcinoma over 10–20 years. Its pathogenesis is complex, and involves a state of lipid accumulation due to increased uptake of free fatty acids into the liver, impaired fatty acid beta oxidation, and increased incidence of de novo lipogenesis. Plasma aminotransferases and liver ultrasound are helpful in the diagnosis of NAFLD/NASH, but a liver biopsy is often required for definitive diagnosis. Many new plasma biomarkers and imaging techniques are now available that should improve the ability to diagnose NAFLD noninvasively Due to its complexity and extrahepatic complications, treatment of NAFLD requires a multidisciplinary approach with excellent preventative care, management, and treatment. This review will evaluate our current understanding of NAFLD, with a focus on existing therapeutic approaches and potential pharmacological developments.

scholarly journals Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis

2019 ◽  
Vol 19 (3) ◽  
pp. 187-198 ◽  
Author(s):  
Jia-Zhen Zhang ◽  
Jing-Jing Cai ◽  
Yao Yu ◽  
Zhi-Gang She ◽  
Hongliang Li
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Current Status ◽  
Imaging Biomarkers ◽  
Nonalcoholic Fatty Liver ◽  
Advantages And Disadvantages ◽  
Diagnostic Approaches

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease and a major cause of related complications such as cirrhosis and hepatocellular carcinoma (HCC). NAFLD progresses through the stages of simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and HCC. However, NAFLD usually cannot be diagnosed in a timely manner, which is largely attributed to the asymptomatic features of NAFLD patients and the lack of an effective and accurate noninvasive screening approach. Although liver biopsy has been recognized as a gold standard for diagnosing NAFLD, this approach is not suitable for screening and monitoring NAFLD because of its high cost and invasiveness. Several noninvasive screening and diagnostic systemic assessments have been developed in recent years for NAFLD evaluation. Here we summarize the current status and methods for NAFLD diagnosis, including both noninvasive (imaging, biomarkers) and invasive (liver biopsy) assessments. We further discuss the advantages and disadvantages of these developed diagnostic approaches for NAFLD.

scholarly journals NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Marinko Marušić ◽  
Matej Paić ◽  
Mia Knobloch ◽  
Ana-Marija Liberati Pršo
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Imaging Techniques ◽  
Excessive Alcohol Consumption ◽  
Numerous Investigation ◽  
Nonalcoholic Fatty Liver ◽  
Diabetes Type Ii

Nonalcoholic fatty liver disease is a condition defined by fat accumulation in hepatocytes not promoted by excessive alcohol consumption. It is highly prevalent and is strongly associated with insulin resistance, metabolic syndrome, and diabetes type II. Insulin resistance plays a crucial role in the multifactorial etiopathogenesis of this condition leading to accumulation of free fatty acids in the liver cells, thus causing lipotoxicity, inflammation, and fibrosis. In this review, we will focus on currently known pathogenesis of nonalcoholic fatty liver disease. Numerous investigation strategies are available to establish the diagnosis, from biochemical markers and ultrasound to various molecular and advanced imaging techniques and liver biopsy. Prevention is crucial. However, effective and promising therapies are strongly demanded.

scholarly journals Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease

2008 ◽  
Vol 7 (3) ◽  
pp. 212-220 ◽  
Author(s):  
Ernesto Roldan-Valadez ◽  
Rafael Favila ◽  
Manuel Martínez-López ◽  
Misael Uribe ◽  
Nahum Méndez-Sánchez
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Imaging Techniques ◽  
Fat Content ◽  
Nonalcoholic Fatty Liver ◽  
Hepatic Fat

scholarly journals Current status of imaging in nonalcoholic fatty liver disease

2018 ◽  
Vol 10 (8) ◽  
pp. 530-542 ◽  
Author(s):  
Qian Li ◽  
Manish Dhyani ◽  
Joseph R Grajo ◽  
Claude Sirlin ◽  
Anthony E Samir
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Current Status ◽  
Nonalcoholic Fatty Liver
Sign in / Sign up

Export Citation Format

Share Document